[Skip to Navigation]
Views 383
Citations 0
Comment & Response
June 23, 2021

Myocardial Infarction and Evolocumab—Reply

Author Affiliations
  • 1TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 2Deputy Editor, JAMA Cardiology
JAMA Cardiol. 2021;6(10):1222-1223. doi:10.1001/jamacardio.2021.2000

In Reply We thank the letter writers for their interest in our article.1 We appreciate the amplification of our observations related to procedural myocardial infarction (MI) being reduced by evolocumab by Alkhalil, suggesting a role of underlying plaque content, stability, and morphology in addition to procedural characteristics.2 We agree that understanding the biology is of interest and that there are several plausible mechanisms; however, data from clinical outcomes trials, including the timing of separation of event curves, cannot serve to inform this mechanistic question and await further studies.

Add or change institution